Clinical Trials in Cagliari, Italy
70 recruiting
Showing 1–20 of 91 trials
Recruiting
Phase 2Phase 3
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Crohn Disease
Janssen Research & Development, LLC1,092 enrolled358 locationsNCT07196722
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Head and Neck Squamous Cell Carcinoma
Merus B.V.700 enrolled202 locationsNCT06525220
Recruiting
Phase 2
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
Graves Disease
Immunovant Sciences GmbH240 enrolled133 locationsNCT06727604
Recruiting
Phase 3
Pirfenidone to Prevent Fibrosis in Ards.
Acute Respiratory Distress Syndrome (ARDS)
Università Vita-Salute San Raffaele130 enrolled17 locationsNCT05075161
Recruiting
REal-life ON PARKinson's - ITaly (REONPARK-IT)
Parkinson Disease
Bial - Portela C S.A.200 enrolled20 locationsNCT07403799
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
Lymphoblastic Lymphoma, Childhood
University Hospital Muenster683 enrolled228 locationsNCT04043494
Recruiting
Phase 3
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled452 locationsNCT06531824
Recruiting
Pompe Disease Registry Protocol
Pompe DiseaseGlycogen Storage Disease Type II
Genzyme, a Sanofi Company2,000 enrolled272 locationsNCT00231400
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled167 locationsNCT06943872
Recruiting
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
Hereditary Cancer SyndromeHereditary CancerLynch Syndrome+19 more
San Raffaele University300 enrolled5 locationsNCT06708429
Recruiting
ICHARUS: Italian Cooperative HemoAdsorption Study for Relief of Uremic Symptoms
Uremia; ChronicChronic Kidney Disease 5D
Azienda Ospedaliera Brotzu120 enrolled1 locationNCT07522008
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled107 locationsNCT07222137
Recruiting
Phase 3
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Pompe Pregnancy Sub-Registry
Pompe Disease (Late-onset)Glycogen Storage Disease Type II (GSD-II)Glycogenesis 2 Acid Maltase Deficiency
Genzyme, a Sanofi Company20 enrolled35 locationsNCT00567073
Recruiting
Phase 4
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
Heart FailureChronic Lymphocytic Leukaemia
AstraZeneca60 enrolled23 locationsNCT06651970
Recruiting
Phase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Migraine
H. Lundbeck A/S600 enrolled70 locationsNCT05164172
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
HER2-negative Breast CancerAdvanced Breast CancerER Positive Breast Cancer+1 more
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Atrial Fibrillation (AF)
Anthos Therapeutics, Inc.1,900 enrolled734 locationsNCT05712200